Femasys Announces Positive Topline Data from Pivotal Trial for its FDA-Cleared FemaSeed® for the Treatment of Infertility
-- In the severe male factor cohort, findings show 24% of women became pregnant after FemaSeed -- -- FemaSeed pregnancy...
Year: 2024
Agile Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Friday, March 22, 2024
Live Conference Call and Webcast at 8:30 a.m. ETPRINCETON, N.J., March 20, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX),...
Autonomix (NASDAQ: AMIX) to Present at the Benzinga Virtual Healthcare Summit 2024
Live webcast presentation on Wednesday, March 20th at 11:50 AM ET THE WOODLANDS, TX, March 20, 2024 (GLOBE NEWSWIRE) --...
Genece Health Announces New Performance Data to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024
DEL MAR, Calif., March 20, 2024 (GLOBE NEWSWIRE) -- Genece Health, a molecular testing company focused on improving cancer screening...
Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., March 20, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (the “Company” or “Vaxart”) today announced...
PDS Biotechnology Announces Conference Call and Webcast for Business Update and Full Year 2023 Financial Results
PRINCETON, N.J., March 20, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a clinical-stage...
Lumos Pharma Announces that the USPTO Has Granted Patent Protection for Novel Formulation of LUM-201, Extending Exclusivity to 2042
AUSTIN, Texas, March 20, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate...
Nusano to Present Isotope Production Capabilities and Commercialization Plans at 7th Theranostics World Congress
VALENCIA, Calif., March 20, 2024 (GLOBE NEWSWIRE) -- Nusano, a physics company transforming the production of medical radioisotopes, will present...
DiagnaMed Announces BRAIN AGE® Trademark Registration Approved by CIPO
BRAIN AGE® solution is part of the CERVAI™ Brain Health AI Platform CERVAI™ Brain Health TORONTO, March 20, 2024 (GLOBE...
Achieve Life Sciences Announces Data from Cytisinicline ORCA Program to be Presented at the 2024 Society for Research on Nicotine and Tobacco (SRNT) Annual Meeting
SEATTLE and VANCOUVER, British Columbia, March 20, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical...
Entera Bio Announces Robust Pharmacokinetic Data for First-in-Class Oral GLP-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome
Pharmacokinetic Profile of Oral GLP-2 Tablets in Rats (mean±SE, n=15) Pharmacokinetic Profile of Oral GLP-2 Tablets in Rats (mean±SE, n=15)...
Tonix Pharmaceuticals Announces Selection of Two Contract Manufacturing Organizations for the Launch and Commercial Manufacture of Tonmya™ for the Management of Fibromyalgia
Tonmya™ is a potential new first-line, centrally acting non-opioid analgesic for the management of fibromyalgia, supported by positive results from...
Alimera Sciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ATLANTA, March 20, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera” or the “Company”), a global pharmaceutical company...
Lifecore Biomedical Concludes Strategic Evaluation Process, Announces Management Succession and Board Changes
Appoints Paul Josephs, an executive with 25 years of CDMO experience as CEO, to succeed current CEO James Hall following...
Altimmune to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on March 27, 2024
GAITHERSBURG, Md., March 20, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it...
23andMe Initiates Phase 1 Clinical Trial for its Dual Mechanism Antibody, 23ME-01473, Targeting ULBP6
23ME-01473 (‘1473) seeks to restore anti-tumor immunity through NK and T cells by blocking the immunosuppressive effects of soluble ULBP6...
Aurora Spine Corporation Celebrates Second Anniversary of Initial Implantation of the World’s First Bone Density Matched DEXA-C Cervical Interbody Fusion Device
CARLSBAD, Calif., March 20, 2024 (GLOBE NEWSWIRE) -- Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV: ASG) (OTCQB: ASAPF),...
MindBio Begins Landmark Phase 2B Take-Home Microdosing (MB22001) Clinical Trial in Patients with Major Depressive Disorder
First doses of MB22001 administered in Phase 2B take-home trial in patients with Major Depressive Disorder.Follows successful Phase 2A trial...
Cosmo Reports Excellent Preliminary Unaudited Full Year 2023 Core Financial Results – Record Guidance for 2024 – Doubles Dividend to 2.00 per Share
Ad hoc announcement pursuant to Art. 53 LR Medtronic deal accounted in 2024, to inject USD 200m cash. FDA approval...
Poolbeg Pharma PLC Announces POLB 001 US Patent Update
Notice of Allowance for Significant POLB 001 Patent in United StatesNotice of Allowance for Immunomodulator II further strengthens robust intellectual...